This time, we focused on a company that plays a key role in gene therapy and innovation in the treatment of rare and serious diseases. It has a deal with the FDA that should accelerate development and access to their drugs and therapies. Besides, it is also worth mentioning that although the company is still loss-making, analysts predict a promising future for it and expect growth in the upper tens to hundreds of percent range.

Healthcare as an industry is undergoing a dynamic evolution, with earnings expected to grow at a compound annual growth rate (CAGR) of 7% through 2027, which is expected to push the value of this market to approximately $819 billion. This positive outlook reflects the growing demand for innovative therapeutic approaches that provide better solutions for patients with unsatisfactory treatment.

Company introduction

uniQure N.V. $QURE is an innovative biotechnology company focused on developing and commercializing gene therapies for patients suffering from rare and…